Status:
COMPLETED
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Lead Sponsor:
AstraZeneca
Conditions:
Gastric Ulcer
Duodenal Ulcer
Eligibility:
All Genders
Brief Summary
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AM...
Detailed Description
Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer
- Exclusion Criteria:
- \- H.pylori negative at the time when the triple therapy is started
Exclusion
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT01435525
Start Date
September 1 2011
End Date
March 1 2014
Last Update
April 16 2014
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan
2
Research Site
Akita, Japan
3
Research Site
Chiba, Japan
4
Research Site
Ehime, Japan